RYTM News and Press, Rhythm Pharmaceuticals Inc. From 03/27/23

- Interview-based research published in Advances in Therapy demonstrates setmelanotide improved hyperphagia and reduced body weight and obsessive focus on food – - Company also announces publication of health state utilities study in hyperphagia - BOSTON, March 27, 2023 (...

2023-03-21 14:58:24 ET Leading weight loss drug developers are on the decline after clinical-stage biotech Altimmune ( NASDAQ: ALT ) announced Phase 1 and Phase 2 results for its lead candidate, pemvidutide sending its shares more than 50% lower on Tuesday. Citing toplin...

2023-03-15 13:24:40 ET Summary Rhythm Pharmaceuticals focuses on rare genetic disorders of obesity and its lead drug, Imcivree, treats obesity due to specific genetic deficiencies. Imcivree's use is limited to specific genetic disorders that affect a small number of patients, whic...

2023-03-12 13:00:16 ET New weight loss therapies could cause a significant strain on Medicare due to cost implications, a group of health experts warned last week in an article published in The New England Journal of Medicine on Saturday amid legislative efforts to gain coverage. ...

2023-03-10 15:07:43 ET Rhythm Pharmaceuticals ( NASDAQ: RYTM ) said Friday that it has ~$3.4M in deposit accounts at Silicon Valley Bank ( SIVB ), which the FDIC has just taken over . The pharma said the cash on deposit at the bank represents ~1.1% of its overa...

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2022 Earnings Conference Call March 1, 2023 08:00 AM ET Company Participants David Connolly - Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer Chien - Executiv...

The following slide deck was published by Rhythm Pharmaceuticals, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Rhythm Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation

Rhythm Pharmaceuticals press release ( NASDAQ: RYTM ): Q4 GAAP EPS of -$0.75 beats by $0.07 . Revenue of $8.8M (+383.5% Y/Y) beats by $1.64M . As of December 31, 2022, cash, cash equivalents and short-term investments were approximately $333.3 million, as compared to $...

-- IMCIVREE ® U.S. launch for Bardet-Biedl syndrome (BBS) reflects strong demand with more than 200 new prescriptions received since FDA approval -- -- IMCIVREE now available in eight ex-U.S. markets; first commercial sales for BBS expected in Germany in 2Q 2023 -- ...

Rhythm Pharmaceuticals ( NASDAQ: RYTM ) is scheduled to announce Q4 earnings results on Wednesday, March 1st, before market open. The consensus EPS Estimate is -$0.78 (+8.2% Y/Y) and the consensus Revenue Estimate is $7.16M (+293.4% Y/Y). Over the last 1 year, RYTM has beate...